Enanta Pharmaceuticals | ENTA - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 9.39B 4.16B 2026-03
Amgen USD 12.04B 2.91B 2026-03
Anika Therapeutics USD 41.02M 16.46M 2026-03
Arrowhead Research USD 201.64M 112.94M 2025-12
AstraZeneca USD 7.56B 1.85B 2026-03
BioCryst Pharmaceuticals USD 171.59M 164.32M 2026-03
Biogen USD 3.38B 374.2M 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
Gilead Sciences USD 7.56B 234M 2025-12
GlaxoSmithKline GBP 3.44B 292M 2026-03
Halozyme Therapeutics USD 309.75M 175.93M 2026-03
Heron Therapeutics USD 26.12M 2.53M 2026-03
Immunic USD 186.63M 171.15M 2026-03
Incyte USD 4.02B 435.22M 2026-03
Insmed USD 582.19M 71.74M 2026-03
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
J&J USD 21.69B 1.98B 2026-03
Karyopharm Therapeutics USD 60.54M 22.87M 2025-12
Ligand Pharmaceuticals USD 115.08M 59.85M 2026-03
Merck USD 5.33B 9.24B 2026-03
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Novartis USD 6.88B 4.56B 2026-03
Novavax USD 228.36M 12.27M 2026-03
Pfizer USD 1.7B 561M 2026-03
PTC Therapeutics USD 833.99M 150.66M 2026-03
Roche Holding CHF 7.55B 579M 2025-06
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
Vertex Pharmaceuticals USD 7.25B 638.6M 2026-03